Reuters logo
9 个月内
BRIEF-Exelixis announces positive results from phase 2 trial of Cabozantinib vs Sunitinib
2016年10月10日 / 早上6点21分 / 9 个月内

BRIEF-Exelixis announces positive results from phase 2 trial of Cabozantinib vs Sunitinib

1 分钟阅读

Oct 10 (Reuters) - Exelixis Inc :

* Exelixis announces positive results from phase 2 cabosun trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at esmo 2016

* Abozantinib met primary endpoint of improving progression-free survival as compared to sunitinib

* Based on these results, exelixis plans to submit a supplemental new drug application (snda) for cabozantinib Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below